Discover trends, market shifts, and competitive outlooks for the cell and gene therapy industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What is the Anticipated CAGR of the Cell and Gene Therapy Market, and What Factors Will Drive It?

The market size for cell and gene therapy has seen a remarkable increase in the recent past. It is projected to surge from a market value of $12.01 billion in 2024 to a staggering $15.48 billion in 2025, reflecting a compound annual growth rate (CAGR) of 28.9%. Various factors like increased investment in cell and gene therapy, enhanced research and development activities, progress in cancer drug innovation, an upswing in public and private sector collaborations, robust economic growth witnessed in budding markets, augmented healthcare spending, and a rise in expenditure on pharmaceutical research and development contribute to the growth observed in the historic period.

Swift expansion is predicted for the cell and gene therapy market, which is projected to rise to $29.15 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 17.1%. This surge over the forecast period can be credited to factors such as the growing incidence of cancer and chronic illnesses, an increasing elderly population, heightened focus on cell and gene therapy, and upsurge in healthcare spending. Key trends expected during the forecast period encompass emphasis on sophisticated therapies like chimeric antigen receptor (CAR) T-cell therapy, dedication towards various research endeavors and securing funding, executing strategic collaborations to amalgamate cutting-edge technologies, focus on the creation of gene or genome editing instruments, particularly CRISPR, forming partnerships or takeover of rival firms, elevating the count of pipeline investigations to devise cell and gene therapies, and investment in the expansion of manufacturing facilities.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

What External and Internal Drivers Are Contributing to the Growth of theCell and Gene Therapy Market?

Investment stability and amalgamation played key roles in the development of the cell and gene therapy (CGT) market. The potential of the CGT market was realized by 16 of the top 20 revenue-earning biopharmaceutical firms, all of which introduced CGT products into their offerings. The BioIndustry Association (BIA), a UK-based entity that represents the biotech and life sciences industries, noted that in 2023, over 55% of venture capital secured by European enterprises was obtained by UK cell and gene therapy corporations. Typically, the UK is responsible for approximately one third of all European venture capital investments in life sciences, demonstrating the prominence of its CGT sector. The CGT manufacturing capacity has seen stable investments and collaboration, resulting in an amplified production capacity, thus fostering market expansion. To illustrate, in October 2024, Purespring Therapeutics, a UK biotech firm, secured $105 million in funding to assist in the development of gene therapies for kidney diseases, including a phase 1/2 experimental treatment trial for immunoglobulin A nephropathy (IgAN). Adeno-associated viruses (AAVs) are employed by Purespring to deliver its gene therapies to the body.

What Segment Types Define the Cell and Gene Therapy Market Structure?

The cell and gene therapy market covered in this report is segmented –

1) By Product: Cell Therapy, Gene Therapy

2) By Application: Oncology, Neurological Disorders, Other Applications

3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:

1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy

2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3472&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Cell and Gene Therapy Market?

North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Long-Term Trends Are Transforming the Competitive Landscape of the Cell and Gene Therapy Market?

The cell and gene therapy (CGT) market is being revolutionized by Chimeric antigen receptor (CAR) T-cell therapy. This therapeutic approach involves collecting T cells from a patient’s blood, genetically engineering them to develop chimeric antigen receptors (CARs) – a type of modified receptor, and reintroducing these modified T cells back into the patient. These reengineered T cells, possessing unique receptor structures, aid in identifying and targeting cancer cell surface antigens, ultimately leading to the destruction of tumor cells. For example, in June 2022, Bristol-Myers Squibb Company, a US pharmaceutical firm, gained approval from the United States Food and Drug Administration (US FDA) for its CAR T cell therapy Breyanzi. This approval was for treating adult patients suffering from large B-cell lymphoma (LBCL), including the diffuse large B-cell lymphoma. Breyanzi is a unique CAR T cell therapy that uses a patient’s own T cells, which undergo collection and re-engineering to become CAR T cells for reintroduction into the patient as a single-administration treatment.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

What Is the Definition of the Cell and Gene Therapy Market?

Gene therapy involves the transmission of genetic material, typically in the form of a carrier or vector, and the uptake of the gene into the proper body cells. Cell therapy includes introducing cells into the patient with the appropriate function. Some procedures combine cell therapy with gene therapy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3472

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model